Laidlaw & Co. Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $19
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2025
0mins
Source: Benzinga
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCT
Wall Street analysts forecast NVCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCT is 15.67 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.370
Low
10.00
Averages
15.67
High
20.00
Current: 8.370
Low
10.00
Averages
15.67
High
20.00
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
- Clinical Study Initiation: Nuvectis Pharma has announced the initiation of a Phase 1b clinical study of NXP900 in combination with osimertinib, targeting patients with EGFR-mutant non-small cell lung cancer (NSCLC), marking a significant advancement in the company's precision oncology efforts.
- Drug Mechanism: NXP900 is an oral small molecule that effectively inhibits SRC and YES1 kinases, addressing resistance mechanisms in EGFR-mutant patients, which could provide new therapeutic options and enhance clinical efficacy.
- Patient Selection Criteria: The study focuses on patients with unresectable metastatic or locally advanced EGFR-mutant NSCLC who have previously responded to osimertinib, ensuring the relevance and potential effectiveness of the study results, which may provide critical data for future treatment strategies.
- Future Outlook: Nuvectis anticipates that 2026 will be a pivotal year with multiple data readouts from both monotherapy and combination studies, further advancing the clinical development of NXP900 and strengthening the company's competitive position in the oncology market.
Continue Reading
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
- Clinical Study Launch: Nuvectis Pharma announces the initiation of a Phase 1b clinical study combining NXP900 with osimertinib, aimed at providing new treatment options for patients with EGFR-mutant non-small cell lung cancer, marking the company's ongoing innovation in oncology.
- Drug Mechanism: NXP900 is an oral small molecule that effectively inhibits SRC and YES1 kinases, targeting known mechanisms of resistance to EGFR inhibitors, which may enhance clinical efficacy and patient outcomes.
- Patient Selection Criteria: The study focuses on patients with unresectable metastatic or locally advanced EGFR-mutant NSCLC who have previously responded to osimertinib, ensuring the relevance and effectiveness of the study results.
- Future Outlook: Nuvectis CEO Ron Bentsur stated that 2026 is expected to be an exciting year with multiple data readouts from both monotherapy and combination studies, further advancing the clinical development of NXP900.
Continue Reading